What is Summit Therapeutics?
Summit Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of novel medicines, with a primary focus on treating Duchenne muscular dystrophy. Headquartered in Cambridge, UK, the company leverages its expertise to address critical unmet medical needs in rare diseases. Its strategic positioning within the biopharmaceutical sector highlights a commitment to innovation and patient-centric therapeutic solutions.
How much funding has Summit Therapeutics raised?
Summit Therapeutics has raised a total of $1.2B across 4 funding rounds:
Stock Offering
$34.2M
Share Placement
$200M
Stock/Share Issuance
$500M
Stock/Share Issuance
$500M
Stock Issuance/Offering (2015): $34.2M, investors not publicly disclosed
Share Placement (2024): $200M, investors not publicly disclosed
Stock/Share Issuance (2025): $500M supported by Akeso
Stock/Share Issuance (2025): $500M featuring Akeso
Key Investors in Summit Therapeutics
Akeso
Akeso, Inc is a pioneering biopharmaceutical company focused on the research and development of innovative antibody drugs for major diseases such as cancer, autoimmune disorders, and metabolic diseases. The company has developed a unique end-to-end drug research and development platform known as the ACE Platform, which incorporates advanced technologies like Tetrabody and Dual-Shield ADCT. With a commitment to addressing unmet clinical needs globally, Akeso aims to provide affordable innovative antibody drug solutions while creating significant commercial and social value. The company actively seeks strategic partnerships for collaborative product development and licensing both in China and internationally.
What's next for Summit Therapeutics?
With a significant influx of capital, Summit Therapeutics is strategically positioned for accelerated growth and the advancement of its drug development pipeline. The substantial enterprise-level funding suggests a transition towards later-stage clinical trials and potential commercialization efforts. This investment will likely fuel further research and development, expand operational capacity, and strengthen strategic partnerships, aiming to bring innovative treatments to patients suffering from Duchenne muscular dystrophy and other debilitating conditions. The company's trajectory indicates a focus on scaling operations and solidifying its market presence.
See full Summit Therapeutics company page
